Pulmonary Therapy View Homepage


Ontology type: schema:Periodical      Open Access: True


Journal Info

START YEAR

2015

PUBLISHER

Springer Healthcare

LANGUAGE

en

HOMEPAGE

http://link.springer.com/journal/41030

Recent publications latest 20 shown

  • 2019-04-01 Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study
  • 2019-03-13 Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
  • 2019-03-13 Chronic Cough in Adults: Make the Diagnosis and Make a Difference
  • 2019-03-06 Nobody Does it Better: A Patient Physician Perspective of Asthma Management
  • 2019-03-05 Epidemiology of Pulmonary Fibrosis: A Cohort Study Using Healthcare Data in Sweden
  • 2019-02-06 In Vitro Study of the Effect of Breathing Pattern on Aerosol Delivery During High-Flow Nasal Therapy
  • 2019-01-17 Pulmonary Therapy: Looking Back on 2018 and Forward to 2019
  • 2018-12 Home Management of Childhood Asthma Exacerbations
  • 2018-12 Aerosol Delivery to a Critically Ill Patient: A Big Issue Easily Solved by Developing Guidelines
  • 2018-12 COPD and Singing for Lung Health: A Patient and Clinician Perspective
  • 2018-12 And Then There Were Three: Time to Move Onward in COPD Drug Development Beyond LAMA/LABA/ICS at Last?
  • 2018-12 Patients with Asthma Prescribed Once-Daily Fluticasone Furoate/Vilanterol or Twice-Daily Fluticasone Propionate/Salmeterol as Maintenance Treatment: Analysis from a Claims Database
  • 2018-12 Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
  • 2018-12 Evaluation of Rapid Onset of Action of ICS/LABA Combination Therapies on Respiratory Function in Asthma Patients: A Single-Center, Open-Label, Randomized, Crossover Trial
  • 2018-06 Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
  • 2018-06 A Real-World Evidence Study Assessing the Impact of Adding the Aerobika Oscillating Positive Expiratory Pressure Device to Standard of Care Upon Healthcare Resource Utilization and Costs in Post-Operative Patients
  • 2018-06 Volume Management in Pulmonary Arterial Hypertension Patients: An Expert Pulmonary Hypertension Clinician Perspective
  • 2018-06 Identifying Critical Errors: Addressing Inhaler Technique in the Context of Asthma Management
  • 2018-06 The Role of the Body Clock in Asthma and COPD: Implication for Treatment
  • 2018-06 In Vitro Determination of the Main Effects in the Design of High-Flow Nasal Therapy Systems with Respect to Aerosol Performance
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H33134", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Pneumology/Respiratory System", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H69000", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Pharmacotherapy", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H24003", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "General Practice / Family Medicine", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H33002", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Internal Medicine", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H69020", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Pharmacoeconomics and Health Outcomes", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H65000", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Quality of Life Research", 
            "type": "DefinedTerm"
          }
        ], 
        "description": "

    Aims and Scope

    Pulmonary Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad and will consider all scientifically sound research from clinical (all phases), observational, real-world, and health outcomes research around the use of pulmonary therapies, devices, and surgical techniques.

    Areas of focus include, but are not limited to: asthma; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; pulmonary hypertension; cystic fibrosis; lung cancer; respiratory tract disorders; allergic rhinitis and other respiratory allergies; influenza, pneumococcal infection, respiratory syncytial virus and other respiratory infections; and inhalers and other device therapies.

    The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols\u00a0and short communications such as commentaries and editorials. Pulmonary Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals.

    Rapid Publication

    The journal\u2019s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3\u20134 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal\u2019s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of pulmonary therapies.

    Personal Service

    The journal\u2019s dedicated in-house editorial team offer a personal \u201cconcierge service\u201d meaning authors will always have an editorial contact able to update them on the status of their manuscript.\u00a0 The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research.

    Enhanced Digital Features

    Pulmonary Therapy offers a range of additional enhanced digital features designed to increase visibility, readership, and the educational value of the content. Each paper is accompanied by a bulleted summary slide, giving a time-efficient overview of the content to a wide readership. Articles also have the option to include other enhanced digital features including (but not limited to) slide sets, videos, video abstracts, podcasts, infographics and animations. All these enhanced digital features are open access and are peer reviewed to the same high standard as the article itself. By having a choice of media not limited to text, figures and tables alone, readers may receive information more effectively, whilst being reassured that the content has undergone the same rigorous peer review as the original article.\u00a0 Offering succinct multimedia formats can support time-pressed healthcare professionals in keeping on top of recently published research. For questions relating specifically to these features, please contact adisdigitalfeatures@springer.com.
    \u00a0
    Plain Language Summaries

    Articles published in Pulmonary Therapy may be accompanied by plain language summaries to assist non-experts (including non-specialists, patients, caregivers and others) in understanding important medical advances. Both the enhanced digital features and plain language summaries can help to reach a broader audience thus supporting the effective dissemination of research.

    Publication Fees

    Upon acceptance of an article, authors will be required to pay the article processing charge and open access fee of \u20ac340/ $380 per typeset page. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis. Considering the time and effort required for a detailed peer review we also reward our regular reviewers with the opportunity to publish without article processing charges (pending peer review) for every three reviews completed per calendar year.\u00a0

    Peer Review Process

    Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria.

    At least two extensive reviews are required to make the editorial decision. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case by case basis and should be sent to the journal editor.

    Copyright

    Pulmonary Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0.

    Contact

    For more information about the journal, including pre-submission enquiries, please contact christopher.vautrinot@springer.com.

    ", "id": "sg:journal.1136859", "inLanguage": [ "en" ], "isAccessibleForFree": true, "issn": [ "2364-1754", "2364-1746" ], "license": "Fully Open Access", "name": "Pulmonary Therapy", "productId": [ { "name": "springer_id", "type": "PropertyValue", "value": [ "41030" ] }, { "name": "nlm_unique_id", "type": "PropertyValue", "value": [ "101687144" ] }, { "name": "dimensions_id", "type": "PropertyValue", "value": [ "136859" ] } ], "publisher": { "name": "Springer Healthcare", "type": "Organization" }, "publisherImprint": "Adis", "sameAs": [ "https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1136859" ], "sdDataset": "journals", "sdDatePublished": "2019-03-18T11:05", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "file:///home/ubuntu/piotr/scigraph_export/journals_20190313_sn_only.jsonl", "startYear": "2015", "type": "Periodical", "url": "http://link.springer.com/journal/41030" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/journal.1136859'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/journal.1136859'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/journal.1136859'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/journal.1136859'


     

    This table displays all metadata directly associated to this object as RDF triples.

    58 TRIPLES      19 PREDICATES      28 URIs      18 LITERALS      5 BLANK NODES

    Subject Predicate Object
    1 sg:journal.1136859 schema:about sg:ontologies/product-market-codes/H24003
    2 sg:ontologies/product-market-codes/H33002
    3 sg:ontologies/product-market-codes/H33134
    4 sg:ontologies/product-market-codes/H65000
    5 sg:ontologies/product-market-codes/H69000
    6 sg:ontologies/product-market-codes/H69020
    7 schema:description <p><b>Aims and Scope<br/></b><br/><i>Pulmonary Therapy</i> is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad and will consider all scientifically sound research from clinical (all phases), observational, real-world, and health outcomes research around the use of pulmonary therapies, devices, and surgical techniques.<br/><br/>Areas of focus include, but are not limited to: asthma; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; pulmonary hypertension; cystic fibrosis; lung cancer; respiratory tract disorders; allergic rhinitis and other respiratory allergies; influenza, pneumococcal infection, respiratory syncytial virus and other respiratory infections; and inhalers and other device therapies.<br/><br/>The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols and short communications such as commentaries and editorials. <i>Pulmonary Therapy</i> will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. <br/><br/><b>Rapid Publication</b><br/><br/>The journal’s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3–4 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of pulmonary therapies.<br/><br/><b>Personal Service</b><br/><br/>The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning authors will always have an editorial contact able to update them on the status of their manuscript.  The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. <br/><br/><b>Enhanced Digital Features</b><br/><br/><i>Pulmonary Therapy</i> offers a range of additional enhanced digital features designed to increase visibility, readership, and the educational value of the content. Each paper is accompanied by a bulleted summary slide, giving a time-efficient overview of the content to a wide readership. Articles also have the option to include other enhanced digital features including (but not limited to) slide sets, videos, video abstracts, podcasts, infographics and animations. All these enhanced digital features are open access and are peer reviewed to the same high standard as the article itself. By having a choice of media not limited to text, figures and tables alone, readers may receive information more effectively, whilst being reassured that the content has undergone the same rigorous peer review as the original article.  Offering succinct multimedia formats can support time-pressed healthcare professionals in keeping on top of recently published research. For questions relating specifically to these features, please contact adisdigitalfeatures@springer.com.<br/> <br/><b>Plain Language Summaries</b><br/><br/>Articles published in <i>Pulmonary Therapy</i> may be accompanied by plain language summaries to assist non-experts (including non-specialists, patients, caregivers and others) in understanding important medical advances. Both the enhanced digital features and plain language summaries can help to reach a broader audience thus supporting the effective dissemination of research.<br/><br/><b>Publication Fees<br/></b><br/>Upon acceptance of an article, authors will be required to pay the article processing charge and open access fee of €340/ $380 per typeset page. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis. Considering the time and effort required for a detailed peer review we also reward our regular reviewers with the opportunity to publish without article processing charges (pending peer review) for every three reviews completed per calendar year.  <br/><br/><b>Peer Review Process</b><br/><br/>Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria.<br/><br/>At least two extensive reviews are required to make the editorial decision. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case by case basis and should be sent to the journal editor.<br/><br/><b>Copyright</b><br/><br/><i>Pulmonary Therapy</i> is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0.<br/><br/><b>Contact<br/><br/></b>For more information about the journal, including pre-submission enquiries, please contact christopher.vautrinot@springer.com.</p>
    8 schema:inLanguage en
    9 schema:isAccessibleForFree true
    10 schema:issn 2364-1746
    11 2364-1754
    12 schema:license Fully Open Access
    13 schema:name Pulmonary Therapy
    14 schema:productId Nc3e1c4fe3ee547318b49b304084ebb44
    15 Nefa8248f0de14903999eeecd36f2b8b7
    16 Nf72bb3aeaa404899b367aaa083d2da4e
    17 schema:publisher N8aa4a3350b63489a952fb2536f7eb80e
    18 schema:publisherImprint Adis
    19 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1136859
    20 schema:sdDatePublished 2019-03-18T11:05
    21 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    22 schema:sdPublisher N5d33186cba6f46fba77f293d26c7a367
    23 schema:startYear 2015
    24 schema:url http://link.springer.com/journal/41030
    25 sgo:license sg:explorer/license/
    26 sgo:sdDataset journals
    27 rdf:type schema:Periodical
    28 N5d33186cba6f46fba77f293d26c7a367 schema:name Springer Nature - SN SciGraph project
    29 rdf:type schema:Organization
    30 N8aa4a3350b63489a952fb2536f7eb80e schema:name Springer Healthcare
    31 rdf:type schema:Organization
    32 Nc3e1c4fe3ee547318b49b304084ebb44 schema:name springer_id
    33 schema:value 41030
    34 rdf:type schema:PropertyValue
    35 Nefa8248f0de14903999eeecd36f2b8b7 schema:name nlm_unique_id
    36 schema:value 101687144
    37 rdf:type schema:PropertyValue
    38 Nf72bb3aeaa404899b367aaa083d2da4e schema:name dimensions_id
    39 schema:value 136859
    40 rdf:type schema:PropertyValue
    41 sg:ontologies/product-market-codes/H24003 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    42 schema:name General Practice / Family Medicine
    43 rdf:type schema:DefinedTerm
    44 sg:ontologies/product-market-codes/H33002 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    45 schema:name Internal Medicine
    46 rdf:type schema:DefinedTerm
    47 sg:ontologies/product-market-codes/H33134 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    48 schema:name Pneumology/Respiratory System
    49 rdf:type schema:DefinedTerm
    50 sg:ontologies/product-market-codes/H65000 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    51 schema:name Quality of Life Research
    52 rdf:type schema:DefinedTerm
    53 sg:ontologies/product-market-codes/H69000 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    54 schema:name Pharmacotherapy
    55 rdf:type schema:DefinedTerm
    56 sg:ontologies/product-market-codes/H69020 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    57 schema:name Pharmacoeconomics and Health Outcomes
    58 rdf:type schema:DefinedTerm
     




    Preview window. Press ESC to close (or click here)


    ...